Dear users,
DigiFinex listed Vitalum (VAM) and VAM/USDT spot trading pair on Dec.18th, 2025. Based on the success of the launch of VAM, DigiFinex will launch the VAM/BTC spot trading pair.The specific schedule is as follows:
Trading pair: VAM/BTC
Token Introduction:
Vitalum platform enables seamless collaboration between providers, streamlines clinical operations, andsurfaces actionable insights—turning fragmented systems into connected care.Whether powering smarter diagnostics, optimizing telemedicine workflows, or enhancing patientoutcomes, Vitalum delivers the infrastructure for scalable, intelligent healthcare.
Download DigiFinex APP: https://www.digifinex.com/en-ww/download
Official Register link: https://www.digifinex.com/en-ww/from/C9JT9c?channelCode=ljaUPp
Disclaimer:
Cryptocurrencies inherently come with market risks and volatility, despite their potential for high growth. We strongly advise users to conduct their research as they invest, acknowledging that they do so at their own risk. Your support for DigiFinex is appreciated!
Canadian Market Disclaimer:
The products mentioned is not eligible for the Canadian market in line with the Pre-Registration Undertaking applicable to DigiFinex. Where technologically feasible, DigiFinex has implemented measures to avoid the dissemination of relevant promotional material to Ips originating from within Canada (apply to all new listings and products except BTC/ETH vs Fiat/USDC pairings).
Thank you for your support!
DigiFinex Team
Jan. 16th, 2026
DigiFinex communities：
Telegram Official Community:https://t.me/DigiFinexEN
Official Twitter: https://twitter.com/digifinex
Official Facebook:https://www.facebook.com/digifinex.global
Official Instagram:https://www.instagram.com/digifinex.global
Official Medium: https://medium.com/@digifinex
Official Reddit: https://www.reddit.com/user/DigiFinex/
DigiFinex (digifinex.com) DIGIFINEX LIMITED reserves all rights of this event, including but not limited to adjustment, explanation, and termination at any time.
Comments
0 comments
Article is closed for comments.